Lipigon Pharmaceuticals AB (publ) (FRA:9RP)
Germany flag Germany · Delayed Price · Currency is EUR
0.0010
-0.0024 (-70.59%)
At close: Dec 5, 2025

FRA:9RP Statistics

Total Valuation

FRA:9RP has a market cap or net worth of EUR 663,596. The enterprise value is -851,106.

Market Cap 663,596
Enterprise Value -851,106

Important Dates

The last earnings date was Friday, November 21, 2025.

Earnings Date Nov 21, 2025
Ex-Dividend Date n/a

Share Statistics

Current Share Class 605.93M
Shares Outstanding n/a
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Insiders (%) 1.13%
Owned by Institutions (%) 6.59%
Float 581.69M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 5.57
PB Ratio 0.49
P/TBV Ratio 0.49
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings 0.26
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF 0.33

Financial Position

The company has a current ratio of 5.95

Current Ratio 5.95
Quick Ratio 5.80
Debt / Equity n/a
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage -137.79

Financial Efficiency

Return on equity (ROE) is -214.35% and return on invested capital (ROIC) is -138.05%.

Return on Equity (ROE) -214.35%
Return on Assets (ROA) -118.45%
Return on Invested Capital (ROIC) -138.05%
Return on Capital Employed (ROCE) -245.59%
Revenue Per Employee 17,018
Profits Per Employee -464,775
Employee Count 7
Asset Turnover 0.07
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +900.00% in the last 52 weeks.

Beta (5Y) n/a
52-Week Price Change +900.00%
50-Day Moving Average 0.01
200-Day Moving Average 0.01
Relative Strength Index (RSI) 19.97
Average Volume (20 Days) n/a

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, FRA:9RP had revenue of EUR 119,124 and -3.25 million in losses. Loss per share was -0.01.

Revenue 119,124
Gross Profit -2.41M
Operating Income -3.35M
Pretax Income -3.25M
Net Income -3.25M
EBITDA -3.34M
EBIT -3.35M
Loss Per Share -0.01
Full Income Statement

Balance Sheet

The company has 1.50 million in cash and n/a in debt, giving a net cash position of 1.50 million.

Cash & Cash Equivalents 1.50M
Total Debt n/a
Net Cash 1.50M
Net Cash Per Share n/a
Equity (Book Value) 1.36M
Book Value Per Share 0.00
Working Capital 1.34M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -2.56 million and capital expenditures -9,769, giving a free cash flow of -2.57 million.

Operating Cash Flow -2.56M
Capital Expenditures -9,769
Free Cash Flow -2.57M
FCF Per Share n/a
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -2,814.27%
Pretax Margin -2,731.13%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

FRA:9RP does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield n/a
Shareholder Yield n/a
Earnings Yield -490.27%
FCF Yield -387.58%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

FRA:9RP has an Altman Z-Score of -11.23 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -11.23
Piotroski F-Score 1